High incidence of autoimmune alterations in chronic myeloid leukemia patients treated with interferon-α
Open Access
- 25 February 2003
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 72 (3), 170-176
- https://doi.org/10.1002/ajh.10282
Abstract
Interferon‐α is the frontline therapy of the majority of chronic myeloid leukemia (CML) patients who are not eligible for bone marrow transplantation. Many patients are treated for long periods, and there is concern about the long‐term immune effects of its use. Autoimmune disorders in patients treated with IFN‐α may be related to the direct immunomodulating properties of IFN or may be linked to a possible toxic effect in target organs, triggering autoimmunity. On the other hand, the immune effects of IFN may play a role in its therapeutic actions. The aims of our study were to assess the incidence of autoimmune phenomena in these patients, and to measure the possible association between the generation of autoimmune phenomena and the antileukemic effect of IFN α. Therefore, 46 patients with Ph1+ CML in the first chronic phase were studied for the appearance of immune complications, their connection to IFN dose, time of appearance, and the possible association with the response to treatment. Autoimmune abnormalities have been found in 28% of our patients. Moreover, a significant association was found between autoimmune alterations and female sex (P = 0.02, OR 4.5, 95% CI 1.13–17.9) and a longer treatment time (1.6 vs. 4.1 years) (P = 0.02; OR 1.01, 95% CI 1–1.02). The Kaplan–Meier estimated probability of obtaining a cytogenetic response was significantly higher in patients who developed autoimmune alterations (P = 0.049), and this difference was also evident in Cox's analysis when controlling with other potentially confounding variables (P = 0.078). We conclude that CML patients treated with IFN alpha have a high incidence of autoimmune phenomenon. Am. J. Hematol. 72:170–176, 2003.This publication has 26 references indexed in Scilit:
- Low-titre auto-antibodies predict autoimmune disease during interferon-α treatment of chronic hepatitis CJournal of Gastroenterology and Hepatology, 2002
- The direct antiglobulin test is frequently positive in chronic myeloid leukemia patients treated with interferon‐αTransfusion, 1997
- Drugs Recently Associated With Lupus SyndromesLupus, 1994
- Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies.JCI Insight, 1994
- Thyroid autoimmunity and hypothyroidism during long-term treatment with recombinant interferon-alphaClinical and Experimental Immunology, 1992
- Cytokines and endocrine function: an interaction between the immune and neuroendocrine systemsClinical Endocrinology, 1991
- Autoantibodies during α‐interferon therapy for chronic hepatitis BJournal of Medical Virology, 1991
- Autoimmune Diseases: The Failure of Self ToleranceScience, 1990
- PSORIASIS AND ALPHA-INTERFERONThe Lancet, 1986
- Hematologic Remission and Cytogenetic Improvement Induced by Recombinant Human Interferon AlphaAin Chronic Myelogenous LeukemiaThe New England Journal of Medicine, 1986